Skip to main content
Supplement ScienceSupplementScience

DIM (Diindolylmethane) Research & Evidence

·

This content is for informational purposes only and does not constitute medical advice. Statements about dietary supplements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary — consult your healthcare provider before starting any supplement. Full disclaimer

Evidence Level

Moderate

DIM is the most biologically relevant metabolite of indole-3-carbinol from cruciferous vegetables. Dalessandri et al. (2004) provided key clinical evidence showing DIM supplementation improves the 2:16α-hydroxyestrone ratio in women, supporting favorable estrogen metabolism. Bjeldanes et al. (1991) established the mechanistic basis for DIM's induction of Phase I and Phase II detoxification enzymes through AhR activation. Reed et al. (2005) demonstrated safety and preliminary efficacy in a Phase I cancer prevention trial. A major practical consideration is bioavailability: crystalline DIM is extremely poorly absorbed, and the BioResponse microencapsulated formulation used in most clinical trials provides dramatically superior absorption. Most supplement research and clinical applications use the BioResponse delivery system.

Evidence by Condition

ConditionStudied DoseEvidence
Estrogen metabolism support100-200mg BioResponse DIM dailyModerate
Liver detox enzyme support100-200mg BioResponse DIM dailyModerate
Hormonal acne (estrogen-related)100-150mg BioResponse DIM dailyEmerging
Prostate health (men)100-200mg BioResponse DIM dailyEmerging
See which DIM (Diindolylmethane) products match the research
Products ranked against the clinical evidence
Full DIM (Diindolylmethane) Guide

References

  1. Dalessandri KM, Firestone GL, Fitch MD, Bradlow HL, Bjeldanes LF (2004). Pilot study: effect of 3,3'-diindolylmethane supplements on urinary hormone metabolites in postmenopausal women with a history of early-stage breast cancer. Nutrition and Cancer. DOI PubMed
  2. Bjeldanes LF, Kim JY, Grose KR, Bartholomew JC, Bradfield CA (1991). Aromatic hydrocarbon responsiveness-receptor agonists generated from indole-3-carbinol in vitro and in vivo: comparisons with 2,3,7,8-tetrachlorodibenzo-p-dioxin. Proceedings of the National Academy of Sciences. DOI PubMed
  3. Reed GA, Sunega JM, Sullivan DK, Gray JC, Mayo MS, Crowell JA, Hurwitz A (2005). Single-dose pharmacokinetics and tolerability of absorption-enhanced 3,3'-diindolylmethane in healthy subjects. Cancer Epidemiology, Biomarkers & Prevention. DOI PubMed
  4. Le HT, Schaldach CM, Bheldanes LF, Firestone GL (2003). Plant-derived 3,3'-Diindolylmethane is a strong androgen antagonist in human prostate cancer cells. Journal of Biological Chemistry. DOI PubMed